Myalgic Encephalomyelitis/Chronic Fatigue Syndrome After SARS-CoV-2 Infection
Elizabeth R Unger,Jin-Mann S Lin,Lauren E Wisk,Huihui Yu,Michelle L'Hommedieu,Helen Lavretsky,Juan Carlos C Montoy,Michael A Gottlieb,Kristin L Rising,Nicole L Gentile,Michelle Santangelo,Arjun K Venkatesh,Robert M Rodriguez,Mandy J Hill,Rachel E Geyer,Efrat R Kean,Sharon Saydah,Samuel A McDonald,Ryan Huebinger,Ahamed H Idris,Jocelyn Dorney,Bala Hota,Erica S Spatz,Kari A Stephens,Robert A Weinstein,Joann G Elmore,Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE) Group,Katherine Koo,Antonia Derden,Kristyn Gatling,Diego Guzman,Geoffrey Yang,Amro Marshall Kaadan,Minna Hassaballa,Ryan Jerger,Zohaib Ahmed,Michael Choi,Ariana Pavlopoulos,Avinash Kesari,Caitlin A Gaylord,Chloe Gomez,Elizabeth Lomas,Phouthavang Jimmie Boliboun,Krisna Patel,Caitlin Malicki,Zhenqiu Lin,Shu-Xia Li,Imtiaz Ebna Mannan,Zimo Yang,Mengni Liu,Andrew Ulrich,Jeremiah Kinsman,Senyte Pierce,Xavier Puente,Wafa Salah,Graham Nichol,Jill Anderson,Mary Schiffgens,Dana Morse,Karen Adams,Tracy Stober,Zenoura Maat,Kelli N O'Laughlin,Michael Willis,Zihan Zhang,Gary Chang,Victoria Lyon,Robin E Klabbers,Luis Ruiz,Kerry Malone,Jasmine Park,Nicole Renzi,Phillip Watts,Morgan Kelly,Kevin Schaeffer,Dylan Grau,David Cheng,Carly Shutty,Alex Charlton,Lindsey Shughart,Hailey Shughart,Grace Amadio,Jessica Miao,Paavali Hannikainen,Chris Chandler,Kate Diaz Roldan,Megan Eguchi,Raul Moreno,Ralph C Wang,Robin Kemball,Virginia Chan,Cecilia Lara Chavez,Angela Wong,Mireya Arreguin,Arun Kane,Peter Nikonowicz,Sarah Sapp,David Gallegos,Katherine R Martin,Ian D Plumb,Aron J Hall,Melissa Briggs-Hagen
DOI: https://doi.org/10.1001/jamanetworkopen.2024.23555
2024-07-01
Abstract:Importance: Chronic symptoms reported following an infection with SARS-CoV-2, such as cognitive problems, overlap with symptoms included in the definition of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Objective: To evaluate the prevalence of ME/CFS-like illness subsequent to acute SARS-CoV-2 infection, changes in ME/CFS symptoms through 12 months of follow-up, and the association of ME/CFS symptoms with SARS-CoV-2 test results at the acute infection-like index illness. Design, setting, and participants: This prospective, multisite, longitudinal cohort study (Innovative Support for Patients with SARS-CoV-2 Infections Registry [INSPIRE]) enrolled participants from December 11, 2020, to August 29, 2022. Participants were adults aged 18 to 64 years with acute symptoms suggestive of SARS-CoV-2 infection who received a US Food and Drug Administration-approved SARS-CoV-2 test at the time of illness and did not die or withdraw from the study by 3 months. Follow-up surveys were collected through February 28, 2023. Exposure: COVID-19 status (positive vs negative) at enrollment. Main outcome and measures: The main outcome was the weighted proportion of participants with ME/CFS-like illness based on the 2015 Institute of Medicine clinical case definition using self-reported symptoms. Results: A total of 4378 participants were included in the study. Most were female (3226 [68.1%]). Mean (SD) age was 37.8 (11.8) years. The survey completion rates ranged from 38.7% (3613 of 4738 participants) to 76.3% (1835 of 4738) and decreased over time. The weighted proportion of participants identified with ME/CFS-like illness did not change significantly at 3 through 12 months of follow-up and was similar in the COVID-19-positive (range, 2.8%-3.7%) and COVID-19-negative (range, 3.1%-4.5%) groups. Adjusted analyses revealed no significant difference in the odds of ME/CFS-like illness at any time point between COVID-19-positive and COVID-19-negative individuals (marginal odds ratio range, 0.84 [95% CI, 0.42-1.67] to 1.18 [95% CI, 0.55-2.51]). Conclusions and relevance: In this prospective cohort study, there was no evidence that the proportion of participants with ME/CFS-like illness differed between those infected with SARS-CoV-2 vs those without SARS-CoV-2 infection up to 12 months after infection. A 3% to 4% prevalence of ME/CFS-like illness after an acute infection-like index illness would impose a high societal burden given the millions of persons infected with SARS-CoV-2.